The role of MET in chemotherapy resistance
GE Wood, H Hockings, DM Hilton, S Kermorgant - Oncogene, 2021 - nature.com
Chemotherapy remains the mainstay of treatment in the majority of solid and haematological
malignancies. Resistance to cytotoxic chemotherapy is a major clinical problem and …
malignancies. Resistance to cytotoxic chemotherapy is a major clinical problem and …
MSP–RON signalling in cancer: pathogenesis and therapeutic potential
Since the discovery of MSP (macrophage-stimulating protein; also known as MST1 and
hepatocyte growth factor-like (HGFL)) as the ligand for the receptor tyrosine kinase RON …
hepatocyte growth factor-like (HGFL)) as the ligand for the receptor tyrosine kinase RON …
Developing c-MET pathway inhibitors for cancer therapy: progress and challenges
X Liu, RC Newton, PA Scherle - Trends in molecular medicine, 2010 - cell.com
Successfully developed target-based therapies have significantly changed cancer treatment.
Among many targets, the c-MET receptor tyrosine kinase and its ligand hepatocyte growth …
Among many targets, the c-MET receptor tyrosine kinase and its ligand hepatocyte growth …
[HTML][HTML] Development of a two-stage gene selection method that incorporates a novel hybrid approach using the cuckoo optimization algorithm and harmony search …
For each cancer type, only a few genes are informative. Due to the so-called 'curse of
dimensionality'problem, the gene selection task remains a challenge. To overcome this …
dimensionality'problem, the gene selection task remains a challenge. To overcome this …
Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors
EC Smyth, F Sclafani, D Cunningham - OncoTargets and therapy, 2014 - Taylor & Francis
The MET/hepatocyte growth-factor (HGF) signaling pathway plays a key role in the
processes of embryogenesis, wound healing, and organ regeneration. Aberrant activation of …
processes of embryogenesis, wound healing, and organ regeneration. Aberrant activation of …
A new optimal gene selection approach for cancer classification using enhanced Jaya-based forest optimization algorithm
In microarray experiments, the sample size is considerably smaller than that of the feature
size, thereby imposing the curse of dimensionality problem. To resolve this issue …
size, thereby imposing the curse of dimensionality problem. To resolve this issue …
The potential therapeutic and prognostic impacts of the c‐MET/HGF signaling pathway in colorectal cancer
SM Parizadeh, R Jafarzadeh‐Esfehani… - IUBMB …, 2019 - Wiley Online Library
Colorectal cancer (CRC) is the third most common cancer and a common cause of cancer‐
related mortality globally. In spite of the improvements in the early diagnosis of CRC …
related mortality globally. In spite of the improvements in the early diagnosis of CRC …
Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer?
Background The KRAS mutation is not responsible for all cases of resistance to anti–
epidermal growth factor receptors (EGFRs) in metastatic colorectal cancer (mCRC), and new …
epidermal growth factor receptors (EGFRs) in metastatic colorectal cancer (mCRC), and new …
Targeting isoforms of RON kinase (MST1R) drives antitumor efficacy
J Kim, DI Koh, M Lee, YS Park, SW Hong… - Cell Death & …, 2023 - nature.com
Recepteur d'origine nantais (RON, MST1R) is a single-span transmembrane receptor
tyrosine kinase (RTK) aberrantly expressed in numerous cancers, including various solid …
tyrosine kinase (RTK) aberrantly expressed in numerous cancers, including various solid …
The c-Met receptor: Implication for targeted therapies in colorectal cancer
E Safaie Qamsari, S Safaei Ghaderi, B Zarei… - Tumor …, 2017 - journals.sagepub.com
c-Met (mesenchymal–epithelial transition factor) is a tyrosine kinase receptor activated by
hepatocyte growth factor and regulates multiple biological processes, such as cell …
hepatocyte growth factor and regulates multiple biological processes, such as cell …